Year: 2021

Nilfisk, a leading provider of professional cleaning products and services, today announced financial results for Q3 2021. Q3 2021 highlightsWe continued to see a positive development in the third quarter of 2021 as seen in the first half of the year with a record volume in demand and order intake. Organic growth was 17.9% for the total business. Revenue was 239.2 mEUR driven by higher order intake across all regions and segments. The growth is the continued result of a broad-based market recovery combined with the successful activation of several business initiatives The branded professional business posted organic growth of 16.1%, in particular driven by strong performance in the Americas and in key markets in other regions Americas posted organic growth of 20.9% mainly driven by strong order intake in the US as a result of our increased...

November 24, 2021 NORDIC SHIPHOLDING A/SCompany Announcement: 16/2021 Published via NASDAQ OMX on November 24, 2021Q3 Result 2021 SummaryThe comparison figures for the period ended 30 September 2020 are stated in parenthesis. The Group extended its loss in the first nine months of this year as the Time Charter Equivalent (“TCE”) rates continued to be depressed due to reduced tonnage demand caused partially by the COVID-19 pandemic, coupled with an excessive tonnage availability in the market. The average daily TCE rate earned in Q3 2021 and 9M 2021 by the vessels was 65% and 58% lower than the average daily TCE rate earned in Q3 2020 and 9M 2020, respectively. The Group incurred a loss after tax of USD 8.1 million (including one-off impairment loss of USD 4.9 million on the vessels) in 9M 2021 compared to a loss after tax of USD 3.9...

ISELIN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 40,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about November 29, 2021, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. Outlook...

The integration of technology is probably the best thing that could have happened to commerce. Not only it is now possible to perform digital transactions and payments from/to anywhere in the world, but the entire commerce system has also now shifted to the internet, thanks to modern technology. But, things do not stop just here. As the world becomes more connected and the mobile economy grows, there is a timely need for a more robust, secure and overall efficient e-commerce system. Blockchain technology has helped make some significant improvements in the e-commerce space. While many online platforms have started accepting cryptocurrencies to allow their international clients an easier & convenient way to pay for their orders, many new projects in this space have emerged that are fully based on blockchain and utilising its power...

VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) — Madison Pacific Properties Inc. (the Company) (TSX: MPC and MPC.C), a Vancouver-based real estate company announces the results of operations for the year ended August 31, 2021. The results reported are pursuant to International Financial Reporting Standards (IFRS) for public companies. For the year ended August 31, 2021, the Company is reporting net income of $53.6 million (2020: $30.1 million); cash flows from operating activities before changes in non-cash operating balances of $10.4 million (2020: $13.1 million); and income per share of $0.86 (2020: $0.51). Included in net income is an after-tax net gain from the fair value adjustment on investment properties of $39.1 million (2020: $21.6 million). The Company currently owns approximately $689 million in investment...

PHILADELPHIA, PA, Nov. 23, 2021 (GLOBE NEWSWIRE) — FTAC Zeus Acquisition Corp. (NASDAQ:ZINGU) (the “Company”), a blank-check company led by Daniel G. Cohen as Chairman of the Board and Ryan M. Gilbert as President and Chief Executive Officer formed for the purpose of acquiring or merging with one or more technology and financial services technology companies, today announced the completion of its initial public offering of 40,250,000 units at a price of $10.00 per unit, which includes 5,250,000 units issued pursuant to the full exercise of the underwriter’s over-allotment option, for gross proceeds to the Company of $402,500,000. The Company’s units began trading on the Nasdaq Global Market under the symbol “ZINGU” on November 19, 2021. Each unit issued in the offering consists of one share of Class A common stock...

TORONTO, Nov. 23, 2021 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, today reported its unaudited condensed consolidated financial results for the third quarter ended September 30, 2021. The Company’s financial results as well as the Management’s Discussion and Analysis have been filed on SEDAR. All financial figures are in United States dollars (“USD”) unless otherwise indicated. Third Quarter Financial (non-IFRS) and Recent Business Highlights: The Company continued to execute on its stated strategic plan during the third quarter and achieved the following significant milestones during and subsequent to the three months ended...

— Follows important findings from the TATTON1 study of the combination in EGFR inhibitor refractory lung cancer patients whose tumors harbor aberrations of MET — HONG KONG and FLORHAM PARK, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/​AIM:​HCM; HKEX:​13) and AstraZeneca PLC (“AstraZeneca”) (LSE/​STO/​Nasdaq:​AZN) have initiated SACHI, a China Phase III study of ORPATHYS® (savolitinib), an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”), in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor (“EGFR”) TKI, TAGRISSO® (osimertinib). The first patient received their first dose on November 22, 2021. The Phase III trial is a multi-center, open-label, randomized, controlled study in patients with locally advanced or metastatic EGFR...